This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMRI Albany Molecular Research (AMRI) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Albany Molecular Research Stock (NASDAQ:AMRI) Get AMRI alerts:Sign Up Key Stats Today's Range$21.74▼$21.7450-Day Range$21.74▼$21.7452-Week Range$13.01▼$22.17VolumeN/AAverage Volume872,120 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs. Read More Receive AMRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Albany Molecular Research and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRI Stock News HeadlinesHealthcare Contract Development and Manufacturing Organization (CDMO) Strategic Business Research Report 2023-2030October 16, 2024 | uk.finance.yahoo.comFDA Grants Fast Track Designation For Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD)October 9, 2024 | finance.yahoo.comForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock.September 16 at 2:00 AM | Chaikin Analytics (Ad)Curia Unveils Brand Refresh at CPHI WW in MilanOctober 8, 2024 | finance.yahoo.com$6.1 Bn Vaccine Contract Manufacturing Market by Vaccine Type, Workflow, Application, and Region 2024-2032September 5, 2024 | finance.yahoo.comCatholic representative body is ‘deeply sorry’ for abuse in religious schoolsSeptember 3, 2024 | msn.comDrug Discovery Services Market Forecast to 2030: Discover the Leading Strategic and Regional Growth Trends Major Players are Capitalizing OnAugust 30, 2024 | uk.finance.yahoo.comGlobal Drug Discovery Outsourcing Services Market Size To Exceed USD 7.9 Billion By 2033 | CAGR Of 7.59%August 25, 2024 | finance.yahoo.comSee More Headlines AMRI Stock Analysis - Frequently Asked Questions How were Albany Molecular Research's earnings last quarter? Albany Molecular Research Inc (NASDAQ:AMRI) announced its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.21 by $0.14. The biotechnology company had revenue of $102.80 million for the quarter, compared to the consensus estimate of $107.20 million. What other stocks do shareholders of Albany Molecular Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that Albany Molecular Research investors own include Casella Waste Systems (CWST), Bristol Myers Squibb (BMY), Zevra Therapeutics (KMPH), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Alpha Lithium (APHLF) and Denison Mine (DNN). Company Calendar Last Earnings5/10/2016Today9/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:AMRI CIK1065087 Webwww.amriglobal.com Phone+1-518-4640279FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AMRI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albany Molecular Research Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Albany Molecular Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRI Stock Alerts